To test a recombinant human relaxin preparation, developed for potential therapeutic application, for possible hypotensive actions in near-term pregnant rhesus monkeys.Methods:
Groups of four females received 1-hour intravenous infusions of 0, 0.1, or 2.0 mg recombinant human relaxin/kg on gestation day 147 (term = 165 days). Maternal heart rate, electrocardiogram, and diastolic, systolic, and mean arterial pressure; and fetal heart rate were monitored before, during, and after the infusion. After spontaneous delivery, physical, neurobehavioral, and physiologic examinations were conducted on the newborn.Results:
No effects of recombinant human relaxin were detected by statistical analysis or examination of data records.Conclusion:
Intravenous infusion of up to 2.0 mg recombinant human relaxin/kg in conscious pregnant rhesus monkeys had no effect on maternal cardiovascular indices or fetal heart rate.